Clinical to Commercial Drug Substance
Whether we develop your processes here at Emergent or bring in your already developed processes, we are ready to put our expertise to work for your specific IND, NDA, and BLA applications.
Upstream Manufacturing Excellence: Our manufacturing facilities are flexible and scalable with the ability to produce drug substances (depending on the technology platform) in 50L to 1000L bioreactors, 50L to 4000L single-use bioreactors, and 10L to 4000L fermenters.
Downstream Processing Excellence: Capitalizing on best-in-class equipment, single-use containers, chromatography columns, and filtration that can accommodate the methods, technologies, and scales needed for product recovery and purification to support production up to 4000L.